ONE KENDALL SQUARE, CAMBRIDGE, MA
Reports Second Quarter 2026 Financial Results and Corporate Highlights
Announces Second Closing of $100 Million Private Placement
Ex-99.1
News, Material Contracts
Investor Presentation
Reports First Quarter 2026 Financial Results and Corporate Highlights
Annual Report to Security Holders
Michael MacLean Appointed as Class III Director at CAMP4 Therapeutics
Q2
Q1
FY 2025
Q3
FY 2024
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Free Writing Prospectus